SOLO-2 Phase 3 trial

July 27, 2018

Lynparza Maintenance for Ovarian Cancer Takes No Toll on Quality of Life, Study Shows

News

Ovarian cancer patients who responded to platinum-based chemotherapy after failing at least one prior treatment may take Lynparza (olaparib) as maintenance therapy without worrying about their quality of life, a new study ... Read more

September 1, 2017

Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows

News

Women with BRCA-mutated relapsed ovarian cancer whose tumors responded to platinum-based chemotherapy took significantly longer to see their disease progressing when given AstraZeneca’s Lynparza (olaparib) as a maintenance therapy, compared to placebo. In addition to ... Read more

November 4, 2016

Lynparza May Significantly Improve Outcomes for Ovarian Cancer Patients, Trial Shows

News

Certain ovarian cancer patients with BRCA mutations may benefit from maintenance treatment with the PARP inhibitor Lynparza (olaparib). The therapy significantly increases progression-free survival, according to the results of a ... Read more